The American Journal of Medicine
Volume 122, Issue 4 , Pages 317-321 , April 2009

Quinidine Revisited

  • Felix Yang, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Felix Yang, MD, Beth Israel Medical Center Heart Institute, 350 East 17th Street, Baird Hall 5th Floor, New York, NY 10003
    • ,
  • Sam Hanon, MD
    • ,
  • Patrick Lam, MD
    • ,
  • Paul Schweitzer, MD

References 

  1. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol. 1995;76:495–498
  2. Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033–1046
  3. Innes GD, Vertesi L, Dillon EC, Metcalfe C. Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. Ann Emerg Med. 1997;29:126–134
  4. Nichol G, McAlister F, Pham B, et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart. 2002;87:535–543
  5. Selzer A, Wray HW. Quinidine syncope (paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias). Circulation. 1964;30:17–26
  6. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion (A meta-analysis of randomized control trials). Circulation. 1990;82:1106–1116
  7. Southworth MR, Zarembski D, Viana M, Bauman J. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. Am J Cardiol. 1999;83:1629–1632
  8. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049
  9. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction (The Cardiac Arrhythmia Suppression Trial (CAST) Investigators). N Engl J Med. 1989;321:406–412
  10. Moosvi AR, Goldstein S, VanderBrug Medendorp S, et al. Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease. Am J Cardiol. 1990;65:1192–1197
  11. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias (A meta-analysis). Circulation. 1991;84:1977–1983
  12. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164:55–60
  13. Takanaka C, Singh BN. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol. 1990;15:213–221
  14. Zhou JT, Zheng LR, Liu WY. Role of early afterdepolarization in familial long QTU syndrome and torsades de pointes. Pacing Clin Electrophysiol. 1992;15(11 Pt 2):2164–2168
  15. Shimizu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol. 1995;26:1299–1309
  16. Liao WB, Bullard MJ, Kuo CT, et al. Anticholinergic overdose induced torsades de pointes successfully treated with verapamil. Jpn Heart J. 1996;37:925–931
  17. de Paola AA, Veloso HH. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation (SOCESP Investigators. The Cardiology Society of Sao Paulo). Am J Cardiol. 1999;84:1033–1037
  18. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932–1939
  19. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385–1394
  20. Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J. 2004;25:1395–1404
  21. Patten M, Maas R, Karim A, et al. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol. 2006;17:1216–1220
  22. Leahey EB, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA. 1978;240:533–534
  23. Ometto R, Arfiero S, Vincenzi M. [Torsades de pointes induced by quinidine: a case treated successfully with verapamil]. G Ital Cardiol. 1990;20:431–434
  24. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–728
  25. Crijns HJ, Wiesfeld AC, Posma JL, Lie KI. Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias. Br Heart J. 1995;74:408–412
  26. Priori SG, Paganini V, Boccalatte L, Schwartz PJ. [Idiopathic ventricular fibrillation: from a collection of clinical cases to a prospective evaluation. The U-CARE Steering Committee. Unexplained Cardiac Arrest Registry of Europe]. G Ital Cardiol. 1995;25:149–158
  27. Belhassen B, Viskin S, Fish R, et al. Effects of electrophysiologic-guided therapy with class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol. 1999;10:1301–1312
  28. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome (A multicenter report). J Am Coll Cardiol. 1992;20:1391–1396
  29. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659–670
  30. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol. 1987;253(3 Pt 2):H704–H708
  31. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001;12:268–272
  32. Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol. 1999;33:5–15
  33. Antzelevitch C, Yan G, Shimizu W, Burashnikov A. Electrical heterogeneity, the ECG, and cardiac arrhythmias. In:  Zipes D,  Jalife J editor. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders Co; 2000;p. 890–903
  34. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660–1666
  35. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731–1737
  36. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004;27(6 Pt 1):821–823
  37. Marquez MF, Rivera J, Hermosillo AG, et al. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol. 2005;28:870–873
  38. Haghjoo M, Arya A, Heidari A, Sadr-Ameli MA. Suppression of electrical storm by oral quinidine in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2005;16:674
  39. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004;43:1853–1860
  40. Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol. 2006;47:359–364
  41. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004;43:1494–1499
  42. Gussak I, Chaitman BR, Kopecky SL, Nerbonne JM. Rapid ventricular repolarization in rodents: electrocardiographic manifestations, molecular mechanisms, and clinical insights. J Electrocardiol. 2000;33:159–170
  43. Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005;16:54–58

 Funding: None.

 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)01254-0

doi: 10.1016/j.amjmed.2008.11.019

The American Journal of Medicine
Volume 122, Issue 4 , Pages 317-321 , April 2009

Article Tools